We are pleased to announce that Mindray has reached an equity transfer agreement with Beijing Precil Instrument Co., Ltd. (“Precil”) to acquire a controlling stake of the company.
Under the agreement, Mindray will gain access to Precil’s R&D, manufacturing, sales and services capabilities. The company’s thrombotic and hemostatic products will complement Mindray’s existing in-vitro diagnostic products in hematology, biochemistry, urine and microbiology analysis, enabling us to provide even better total solutions to our customers. Precil’s products will help Mindray meet the increasingly stringent requirements for pre-operative screening and cardiovascular disease detection. This acquisition presents another great opportunity for Mindray to continue to expand its marketplace and sustain our rapid business growth.
Mindray has no plan to change Precil’s employee base and will continue all of Precil’s contracts as agreed upon before the acquisition. We will also maintain Precil’s existing policies on sales and after-sales services.
Mindray will leverage its strong platforms in manufacturing, research and development, quality assurance, and sales and marketing to support Precil’s future development. We will work closely with Precil to help strengthen the company’s leading position in China’s thrombotic and hemostatic detection market.
We believe our collaboration with Precil will create many synergies for both parties. Together, we can provide better products and services to our customers and create more career opportunities for our employees.
About Precil:
Based in Shangdi Qunying Technology and Science Park in Beijing, China, Precil is a developer, manufacturer and marketer of coagulation analyzing products in China. It has been leading China’s thrombotic and hemostatic detection market since it was founded in 1994. For more information, please visit www.precil.com.cn.
Shenzhen Mindray Bio-medical Electronics Co., Ltd.
Oct. 31. 2012